Ebensen Thomas, Schulze Kai, Riese Peggy, Link Claudia, Morr Michael, Guzmán Carlos A
Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, 38124 Braunschweig, Germany.
Vaccine. 2007 Feb 9;25(8):1464-9. doi: 10.1016/j.vaccine.2006.10.033. Epub 2006 Nov 3.
The identification of new adjuvants is a critical need in vaccinology. In this work, it is demonstrated that bis-(3',5')-cyclic dimeric guanosine monophosphate (cdiGMP) exhibits potent adjuvant properties. Subcutaneous co-administration of cdiGMP with beta-galactosidase (beta-Gal) to mice resulted in the elicitation of significantly higher antigen-specific serum IgG titres than in animals receiving beta-Gal alone. Strong cellular immune responses, which were characterized by a balanced Th1/Th2 pattern, were also observed in response to the beta-Gal protein and a peptide encompassing its MHC class I-restricted epitope in immunized animals. These results suggest that cdiGMP represents a promising adjuvant for vaccine development.
新型佐剂的鉴定是疫苗学领域的一项迫切需求。在本研究中，已证明双（3'，5'）-环二聚鸟苷单磷酸（cdiGMP）具有强大的佐剂特性。将cdiGMP与β-半乳糖苷酶（β-Gal）皮下共同给予小鼠，与单独接受β-Gal的动物相比，可诱导产生显著更高的抗原特异性血清IgG滴度。在免疫动物中，针对β-Gal蛋白及其包含MHC I类限制性表位的肽，还观察到了以Th1/Th2平衡模式为特征的强烈细胞免疫反应。这些结果表明，cdiGMP是一种有前景的疫苗开发佐剂。
